Noxopharm Limited 48 Note 25. Earnings per share Consolidated 2022 2021 $ $ Loss after income tax attributable to the owners of Noxopharm Limited (18,666,810) (9,346,749) Number Number Weighted average number of ordinary shares used in calculating basic earnings per share 291,221,727 263,850,689 Weighted average number of ordinary shares used in calculating diluted earnings per share 291,221,727 263,850,689 Cents Cents Basic earnings per share (6.41) (3.54) Diluted earnings per share (6.41) (3.54) The 53,953,349 (2021: 56,546,540) options on issue could potentially dilute basic earnings per share in the future, but were not included in the calculation of diluted earnings per share because they are anti-dilutive for the periods presented. Accounting policy for earnings per share Basic earnings per share Basic earnings per share is calculated by dividing the profit attributable to the owners of Noxopharm Limited, excluding any costs of servicing equity other than ordinary shares, by the weighted average number of ordinary shares outstanding during the financial year, adjusted for bonus elements in ordinary shares issued during the financial year. Diluted earnings per share Diluted earnings per share adjusts the figures used in the determination of basic earnings per share to take into account the after income tax effect of interest and other financing costs associated with dilutive potential ordinary shares and the weighted average number of shares assumed to have been issued for no consideration in relation to dilutive potential ordinary shares.
RkJQdWJsaXNoZXIy MjE2NDg3